As filed with the Securities and Exchange Commission on February 12, 2014
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PTC Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware (State or Other Jurisdiction of Incorporation or Organization) |
|
2834 (Primary Standard Industrial Classification Code Number) |
|
04-3416587 (I.R.S. Employer Identification Number) |
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Stuart W. Peltz, Ph.D.
Chief Executive Officer
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
copies to:
David E. Redlick Brian A. Johnson Wilmer Cutler Pickering Hale and New York, New York 10007 Telephone: (212) 230-8800 Fax: (212) 230-8888 |
|
Mark E. Boulding Executive Vice President and Chief Legal PTC Therapeutics, Inc. 100 Corporate Court South Plainfield, New Jersey 07080 Telephone: (908) 222-7000 Fax: (908) 222-1128 |
|
Richard Truesdell, Jr. Davis Polk & Wardwell LLP 450 Lexington Avenue New York, New York 10017 Telephone: (212) 450-4000 Fax: (212) 701-5800 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this Form is filed to register additional securities for an offering pursuant Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-188657
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
|
Accelerated filer o |
Non-accelerated filer x (Do not check if a smaller reporting company) |
|
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
| ||
Title of each class of securities |
|
Proposed maximum |
|
Amount of |
| ||
Common Stock, $0.001 par value per share |
|
$ |
11,500,000 |
|
$ |
1,482 |
|
(1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the offering price of additional shares that the underwriters have the option to purchase.
(2) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This registration statement is being filed with respect to the registration of additional shares of common stock, $0.001 par value per share, of PTC Therapeutics, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-193677), which was declared effective by the Commission on February 12, 2014, are incorporated in this registration statement by reference.
The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of South Plainfield, State of New Jersey, on this 12th day of February, 2014.
|
PTC Therapeutics, Inc. | |
|
| |
|
|
|
|
By: |
/s/ Stuart W. Peltz, Ph.D. |
|
|
Name: Stuart W. Peltz, Ph.D. |
|
|
Title: Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date | |
|
|
|
|
| |
/s/ Stuart W. Peltz, Ph.D. |
|
Chief Executive Officer and Director (principal executive officer) |
|
February 12, 2014 | |
Stuart W. Peltz, Ph.D. |
|
|
| ||
|
|
|
|
| |
/s/ Shane Kovacs |
|
Chief Financial Officer (principal financial and accounting officer) |
|
February 12, 2014 | |
Shane Kovacs |
|
|
| ||
|
|
|
|
| |
* |
|
Chairman of the Board |
|
February 12, 2014 | |
Michael Schmertzler |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Richard Aldrich |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Axel Bolte |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Allan Jacobson, Ph.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Adam Koppel, M.D., Ph.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Michael Kranda |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Geoffrey McDonough, M.D. |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
David P. Southwell |
|
|
|
| |
|
|
|
|
| |
* |
|
Director |
|
February 12, 2014 | |
Jerome B. Zeldis, M.D., Ph.D. |
|
|
|
| |
|
|
|
|
| |
*By: |
/s/ Stuart W. Peltz, Ph.D. |
|
|
|
February 12, 2014 |
|
Name: Stuart W. Peltz, Ph.D. |
|
|
|
|
|
Title: Attorney-in-Fact |
|
|
|
|
EXHIBIT INDEX
Exhibit No. |
|
Description |
5.1 |
|
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP |
23.1 |
|
Consent of Ernst & Young LLP, independent registered public accounting firm |
23.2 |
|
Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) |
24.1* |
|
Powers of Attorney |
* Filed as Exhibit 24.1 to the Registrants Registration Statement on Form S-1 (File No. 333-193677) filed with the Securities and Exchange Commission on January 31, 2014.
Exhibit 5.1
February 12, 2014 |
+1 212 230 8800 (t) +1 212 230 8888 (f) wilmerhale.com |
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
Re: PTC Therapeutics, Inc. Rule 462(b) Registration Statement on Form S-1
Ladies and Gentlemen:
This opinion is furnished to you in connection with a Registration Statement on Form S-1 (File No. 333-193677) (the Registration Statement) filed with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the Securities Act), pursuant to Rule 462(b) of the Securities Act, for the registration of shares of Common Stock, $0.001 par value per share, of PTC Therapeutics, Inc., a Delaware corporation (the Company), with a proposed maximum aggregate offering price of $11,500,000 (the Shares), including Shares issuable upon exercise of an over-allotment option granted by the Company.
The Shares are to be sold by the Company pursuant to an underwriting agreement (the Underwriting Agreement) to be entered into among the Company and the several underwriters named in Schedule 1 thereto, for whom J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as representatives, the form of which has been filed as Exhibit 1.1 to the Registration Statement.
We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings and actions of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and Bylaws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth. In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.
We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the State of New York, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.
Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the
terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption Legal matters. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours,
WILMER CUTLER PICKERING
HALE AND DORR LLP
By: |
/s/ Brian A. Johnson |
|
|
Brian A. Johnson, a Partner |
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement on Form S-1MEF of our report dated March 15, 2013 relating to the financial statements of PTC Therapeutics, Inc., which appears in the Registration Statement on Form S-1/A (No. 333-193677). We also consent to the reference to us under the heading Experts in the prospectus incorporated by reference into this Registration Statement.
/s/ Ernst & Young LLP
Metro Park, New Jersey
February 11, 2014